Michelle A. Pressly

Michelle A. Pressly

Auto-generated profile, based on publicly available information

Michelle A. Pressly

Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, Maryland 20903, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
MPMichelle A. Pressly
Michelle A. Pressly
RPRobert S. Parker
Robert S. Parker
JWJonathan Waters
Jonathan Waters
SBStacy L. Beck
Stacy L. Beck
AJArundhathi Jeyabalan
Arundhathi Jeyabalan
GCGilles Clermont
Gilles Clermont

14 June 2023 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
MPMichelle A. Pressly
Michelle A. Pressly
Stephan SchmidtStephan Schmidt
Stephan Schmidt
DGDaphne Guinn
Daphne Guinn
ZLZhichao Liu
Zhichao Liu
CCCarrie Ceresa
Carrie Ceresa
EFElimika Pfuma Fletcher
Elimika Pfuma Fletcher

1 May 2020 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
MPMichelle A. Bs Pressly
Michelle A. Bs Pressly
RPRobert S. Parker
Robert S. Parker
MNMatthew D. Neal
Matthew D. Neal
JSJason L. Sperry
Jason L. Sperry
GCGilles Clermont
Gilles Clermont
BACKGROUND: Modeling approaches offer a novel way to detect and predict coagulopathy in trauma patients. A dynamic model, built and tested on thromboelastogram (TEG) data, was used to generate a virtual library of over 160,000 simulated RapidTEGs. The patient-specific parameters are the initial platelet count, platelet activation rate, thrombus growth rate, and lysis rate (P(0), k1, k2, and k3, respectively). METHODS: Patient data from both STAAMP (n = 182 patients) and PAMPer (n = 111 patients) clinical trials were collected. A total of 873 RapidTEGs were analyzed. One hundred sixteen TEGs indicated maximum amplitude (MA) below normal and 466 TEGs indicated lysis percent above normal. Each patient's TEG response was compared against the virtual library of TEGs to determine library trajectories having the least sum-of-squared error versus the patient TEG up to each specified evaluation time ∈ (3, 4, 5, 7.5, 10, 15, 20 minutes). Using 10 nearest-neighbor trajectories, a logistic regression was performed to predict if the patient TEG indicated MA below normal (<50 mm), lysis percent 30 minutes after MA (LY30) greater than 3%, and/or blood transfusion need using the parameters from the dynamic model. RESULTS: The algorithm predicts abnormal MA values using the initial 3 minutes of RapidTEG data with a median area under the curve of 0.95, and improves with more data to 0.98 by 10 minutes. Prediction of future platelet and packed red blood cell transfusion based on parameters at 4 and 5 minutes, respectively, provides equivalent predictions to the traditional TEG parameters in significantly less time. Dynamic model parameters could not predict abnormal LY30 or future fresh-frozen plasma transfusion. CONCLUSION: This analysis could be incorporated into TEG software and workflow to quickly estimate if the MA would be below or above threshold value within the initial minutes following a TEG, along with an estimate of what blood products to have on hand. LEVEL OF EVIDENCE: Therapeutic/Care Management: Level IV.

18 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BCBrian Cicali
Brian Cicali
LSLais Da Silva
Lais Da Silva
ASAmir Sarayani
Amir Sarayani
KLKarthik Lingineni
Karthik Lingineni
MPMichelle Pressly
Michelle Pressly
Rodrigo CristofolettiRodrigo Cristofoletti
Rodrigo Cristofoletti

23 November 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
DGDaphne Guinn
Daphne Guinn
MPMichelle A. Pressly
Michelle A. Pressly
ZLZhichao Liu
Zhichao Liu
CCCarrie Ceresa
Carrie Ceresa
SSSherbet Samuels
Sherbet Samuels
EFElimika Pfuma Fletcher
Elimika Pfuma Fletcher

2 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSoyoung Kim
Soyoung Kim
BCBrian Cicali
Brian Cicali
MPMichelle Pressly
Michelle Pressly
LSLais Da Silva
Lais Da Silva
TWThomas Wendl
Thomas Wendl
Rodrigo CristofolettiRodrigo Cristofoletti
Rodrigo Cristofoletti
Levonorgestrel (LNG) is a progestin used in many contraceptive formulations, including subcutaneous implants. There is an unmet need for developing long-acting formulations for LNG. To develop long-acting formulations, release functions need to be investigated for LNG implant. Therefore, a release model was developed and integrated into an LNG physiologically-based pharmacokinetic (PBPK) model. Utilizing a previously developed LNG PBPK model, subcutaneous administration of 150 mg LNG was implemented into the modeling framework. To mimic LNG release, ten functions incorporating formulation-specific mechanisms were explored. Release kinetic parameters and bioavailability were optimized using Jadelle® clinical trial data (n = 321) and verified using two additional clinical trials (n = 216). The First-order release and Biexponential release models showed the best fit with observed data, the adjusted R-squared (R2) value is 0.9170. The maximum released amount is approximately 50% of the loaded dose and the release rate is 0.0009 per day. The Biexponential model also showed good agreement with the data (adjusted R2 = 0.9113). Both models could recapitulate observed plasma concentrations after integration into the PBPK simulations. First-order and Biexponential release functionality may be useful in modeling subcutaneous LNG implants. The developed model captures central tendency of the observed data as well as variability of release kinetics. Future work focuses on incorporating various clinical scenarios into model simulations, including drug-drug interactions and a range of BMIs.